--- title: "Lisata Therapeutics (LSTA) news: offering, merger and layoffs" url: "https://aibio.space/companies/lisata-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "LSTA offering, merger and layoffs news: Lisata cuts 72% of staff after failed Kuva buyout, then merges with Marea. Lisata Therapeutics, Inc." --- LSTA Lisata Therapeutics, Inc. NASDAQ · United States # Lisata Therapeutics (LSTA) news LSTA offering, merger and layoffs news Distress · 2026-08-03 ## [Lisata cuts 72% of staff after failed Kuva buyout, then merges with Marea](https://aibio.space/news/lisata-cuts-72-percent-staff-after-failed-kuva-buyout-then-merges/) Kuva Labs could not raise the money to complete its $4.00 tender offer for Lisata. Lisata then cut about 72% of its staff, and on Sept 17 it bought Marea with a $225 million private placement that heavily dilutes existing holders. ## Latest Lisata Therapeutics news 1. 2026-05-04 Mergers [Lisata and Kuva Labs delay tender offer start to May 29, Kuva to pay up to $1.1 million of expenses](https://aibio.space/news/lisata-kuva-labs-delay-tender-offer-start-may-29-kuva-pay-up-1-1/) Lisata and Kuva Labs signed an amendment and waiver on May 3, 2026 that moves the tender offer start from April 13, 2026 to May 29, 2026. Kuva will pay up to $1.1 million of Lisata's expenses until the offer starts, and the offer is $5.00 in cash plus a $1.00 contingent value right. 2. 2026-04-03 Mergers [Lisata and Kuva Labs push back tender offer start to April 13, 2026](https://aibio.space/news/lisata-kuva-labs-push-back-tender-offer-start-april-13-2026/) Lisata and Kuva Labs agreed on April 2, 2026 to move the tender offer start from April 3 to April 13, 2026, or a later agreed date. The offer pays $5.00 in cash plus a $1.00 contingent right, and Lisata's 10-K says its $16.0 million in cash does not cover twelve months of spending. ## Lisata Therapeutics at a glance - **Ticker**: LSTA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $10.4 million ### Related companies - [Aoxing Pharmaceutical Company](https://aibio.space/companies/aoxing-pharmaceutical/) OTC: AOXG - [Immix Biopharma](https://aibio.space/companies/immix-biopharma/) NASDAQ: IMMX - [Aardvark Therapeutics](https://aibio.space/companies/aardvark-therapeutics/) NASDAQ: AARD - [Pfizer](https://aibio.space/companies/pfizer-pfe/) NYSE: PFE - [Achieve Life Sciences](https://aibio.space/companies/achieve-life-sciences/) NASDAQ: ACHV - [Karyopharm Therapeutics](https://aibio.space/companies/karyopharm-therapeutics/) NASDAQ: KPTI - [Eli Lilly](https://aibio.space/companies/eli-lilly/) NYSE: LLY - [MacroGenics](https://aibio.space/companies/macrogenics/) NASDAQ: MGNX ### Also on NASDAQ - [Generate Biomedicines](https://aibio.space/companies/generate-biomedicines/) GENB - [Celcuity](https://aibio.space/companies/celcuity/) CELC - [Dyne Therapeutics](https://aibio.space/companies/dyne-therapeutics/) DYN - [Zevra Therapeutics](https://aibio.space/companies/zevra-therapeutics/) ZVRA - [Adagio Medical Holdings](https://aibio.space/companies/adagio-medical/) ADGM - [Cardio Diagnostics Holdings](https://aibio.space/companies/cardio-diagnostics/) CDIO ## Lisata Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Net income (loss) | [-$16.6 million](https://www.sec.gov/Archives/edgar/data/320017/000032001726000023/) | [-$20.0 million](https://www.sec.gov/Archives/edgar/data/320017/000032001726000023/) | | Cash from operations | [-$15.9 million](https://www.sec.gov/Archives/edgar/data/320017/000032001726000023/) | [-$19.4 million](https://www.sec.gov/Archives/edgar/data/320017/000032001726000023/) | | Cash and equivalents | [$16.0 million](https://www.sec.gov/Archives/edgar/data/320017/000032001726000038/) | [$16.2 million](https://www.sec.gov/Archives/edgar/data/320017/000032001726000023/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $10.4 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Lisata Therapeutics Has Lisata Therapeutics raised money recently? Our latest story on this, dated Aug 3, 2026: "Lisata cuts 72% of staff after failed Kuva buyout, then merges with Marea". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/lisata-cuts-72-percent-staff-after-failed-kuva-buyout-then-merges/). Is Lisata Therapeutics involved in a merger or acquisition? Our latest story on this, dated Aug 3, 2026: "Lisata cuts 72% of staff after failed Kuva buyout, then merges with Marea". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/lisata-cuts-72-percent-staff-after-failed-kuva-buyout-then-merges/). Has Lisata Therapeutics cut staff? Our latest story on this, dated Aug 3, 2026: "Lisata cuts 72% of staff after failed Kuva buyout, then merges with Marea". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/lisata-cuts-72-percent-staff-after-failed-kuva-buyout-then-merges/). What is the ticker symbol of Lisata Therapeutics? Lisata Therapeutics, Inc. trades under the ticker LSTA on NASDAQ. Where is Lisata Therapeutics listed? Lisata Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:8NE; LSE:0HS8. What is the SEC CIK of Lisata Therapeutics? The SEC Central Index Key (CIK) for Lisata Therapeutics, Inc. is 320017. Its filings are on SEC EDGAR. How many shares does Lisata Therapeutics have outstanding? 9,010,937 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Lisata Therapeutics listed under? Our directory records Lisata Therapeutics, Inc. under United States. What does Lisata Therapeutics do? Our directory classifies Lisata Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Lisata Therapeutics? The ISIN recorded for Lisata Therapeutics, Inc. is US1280583022. Does aibio.space cover Lisata Therapeutics? aibio.space lists Lisata Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Lisata Therapeutics incorporated? SEC records list its state or country of incorporation as DE. Is Lisata Therapeutics profitable? Lisata Therapeutics, Inc. reported a net loss of $16.6 million for the fiscal year ended Dec 31, 2025, and used $15.9 million of cash in operations, per its annual report to the SEC. How much cash does Lisata Therapeutics have? $10.4 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Lisata Therapeutics (LSTA) stock news? Our latest story on Lisata Therapeutics, dated Aug 3, 2026: "Lisata cuts 72% of staff after failed Kuva buyout, then merges with Marea". Kuva Labs could not raise the money to complete its $4.00 tender offer for Lisata. Lisata then cut about 72% of its staff, and on Sept 17 it bought Marea with a $225 million private placement that heavily dilutes existing holders. [Source](https://aibio.space/news/lisata-cuts-72-percent-staff-after-failed-kuva-buyout-then-merges/). ## Investor discussion: Lisata Therapeutics Members talk about Lisata Therapeutics (LSTA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Lisata Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-10-19 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/320017/000114036126039986/ny20082391x2_def14a.htm) 2. 2026-10-07 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/320017/000114036126038937/ny20082391x1_pre14a.htm) 3. 2026-08-04 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/320017/000114036126031028/ef20079399_8k.htm) 4. 2026-07-24 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,8.01). [Source](https://www.sec.gov/Archives/edgar/data/320017/000114036126029541/ef20078724_8k.htm) 5. 2026-05-29 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/320017/000114036126023336/ef20075162_8k.htm) 6. 2026-03-12 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/320017/000032001726000023/lsta-20251231.htm) 7. 2026-01-21 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/320017/000032001726000006/ex991to8-kkuvajanuary2026.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:LSTA on TradingView](https://www.tradingview.com/symbols/NASDAQ-LSTA/). ## SEC filings and registration - **SEC name**: Lisata Therapeutics, Inc. - **CIK**: 320017 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: LSTA (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 110 ALLEN ROAD, BASKING RIDGE, NJ, 07920 - **Phone**: 908-229-2590 - **Shares outstanding**: 9,010,937 as of 2026-08-06 (10-Q filed 2026-08-06) - **Former names**: Caladrius Biosciences, Inc.; CALADRIUS BIOSCIENCES, INC.; NeoStem, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [DEF 14A](https://www.sec.gov/Archives/edgar/data/320017/000114036126039986/ny20082391x2_def14a.htm) filed 2026-10-19 - [8-K](https://www.sec.gov/Archives/edgar/data/320017/000114036126039602/ef20083796_8k.htm) filed 2026-10-14 - [8-K](https://www.sec.gov/Archives/edgar/data/320017/000114036126036866/ef20082158_8k.htm) filed 2026-09-17 - [10-Q](https://www.sec.gov/Archives/edgar/data/320017/000032001726000038/lsta-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/320017/000114036126031028/ef20079399_8k.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/320017/000114036126029541/ef20078724_8k.htm) filed 2026-07-24 - [8-K](https://www.sec.gov/Archives/edgar/data/320017/000114036126028763/ef20078184_8k.htm) filed 2026-07-17 - [8-K](https://www.sec.gov/Archives/edgar/data/320017/000114036126024560/ef20075787_8k.htm) filed 2026-06-09 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000320017), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Lisata Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker LSTA, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Lisata Therapeutics, Inc. - **Ticker**: LSTA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US1280583022 - **Other listed symbols**: GETTEX:8NE; LSE:0HS8 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-LSTA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/lisata-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Lisata Therapeutics (LSTA) news: offering, merger and layoffs", 2026-10-31, https://aibio.space/companies/lisata-therapeutics/